A5057537978- BRCA gene mutations in cancer
- Nutrition, Genetics, and Disease
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Advances in Oncology and Radiotherapy
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Health and Medical Research Impacts
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Nutrition and Health in Aging
- Genetic factors in colorectal cancer
- COVID-19 and healthcare impacts
- Palliative Care and End-of-Life Issues
- Diversity and Career in Medicine
- Immunotherapy and Immune Responses
Institut Paoli-Calmettes
2022-2025
Institut Gustave Roussy
2018-2024
Inserm
2018-2024
Centre National de la Recherche Scientifique
2024
Université Paris-Saclay
2018-2021
Université Paris Cité
2020
École Pratique des Hautes Études
2018
Université Paris-Sud
2018
Centre Pompidou
2014
Hôpital Européen Georges-Pompidou
2014
Abstract Purpose: Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance. Experimental Design: This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by MyChoice CDx (Myriad Genetics). detection...
Background: Breast cancer (BC) incidence increases with age, particularly in HR-positive/HER2-negative subtypes. Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6is) alongside endocrine therapy (ET) have emerged as promising treatments for advanced early BC. However, their efficacy, safety, impact on quality of life (QoL) older frail patients remain underexplored. Methods: This position paper assesses the existing literature from 2015 to 2024, focusing CDK4/6is use aged 65 years Results:...
PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis (CH), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under selective pressure DNA-damaging chemotherapy. However, whether promote development hematologic malignancies remains unclear. We characterized clinical genomic profiles 112 PPM1D-mutated patients across spectrum disorders using combination bulk single-cell...
Introduction During the coronavirus disease 2019 (COVID-19) pandemic, Gustave Roussy Cancer Center introduced teleconsultation via telephone, as an alternative to face-to-face consultation reduce patient hospital visits. This study was designed assess and doctor satisfaction with this modality of care in oncology during period pandemic beyond. Methods We two questionnaires based on validated scores from patients (EORTC OUT-PATSAT 35 Telemedicine Satisfaction Questionnaire [TSQ] scores)...
Although a quarter of cervical cancers occur after the age 65 years, there is no treatment consensus for these patients. The aim this work was to survey how physicians treat patients with advanced cancer, focusing on adjustments according and frailty status. Specialists were invited an online survey. Data collected included information respondent strategy in four cases (FIGO IIb, FIGO IVa, IVb, metastatic recurrence) three scenarios (45-year-old, 75-year-old fit, unfit). We received 237...
Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following results of SOLO-1/GOG 3004 trial as maintenance monotherapy adult patients with BRCA-mutated epithelial ovarian cancer. This study aimed to provide descriptive analysis first real-world data from cancer who received olaparib first-line French cohort Temporary Authorisation for Use (Autorisation Temporaire d'Utilisation de cohorte, ATUc) programme 11 March, 2019 16 January, 2020....
Click here to listen the Podcast At ESMO2020's presidential session I, first results of CheckMate-9ER study were presented by Prof. Tony Chouieri from Dana Farber Cancer Institute. is a randomised controlled trial comparing combination nivolumab and cabozantinib versus long-standing standard sunitinib as first-line treatment for metastatic renal cell carcinoma with clear component any IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) risk group. In this analysis,...
There is a lack of biomarkers to predict outcome following initial treatment in patients with high-grade ovarian cancer. We hypothesized that monitoring
<div>Abstract<p>Purpose: Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade OC clinical behavior assess its relevance. Design: This a retrospective monocentric analysis centrally tested for genomic-instability score (GIS) by MyChoice CDx (Myriad Genetics). detection quantification were...